CoChat
Sign Up
Cited by 127Autism Spectrum Disorder ResearchAttention Deficit Hyperactivity DisorderSchizophrenia research and treatment

Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases

Posey, David J., Puntney, Jessica I., Sasher, Teresa M., Kem, Deborah L., McDougle, Christopher J.·2004·Journal of Child and Adolescent Psychopharmacology
DOI 10.1089/1044546041649084
Open this paper in CoChat — free account

Abstract

OBJECTIVE: The aim of this study was to retrospectively review a large sample of children and adolescents with pervasive developmental disorders (PDDs) treated with open-label guanfacine in order to gather preliminary data as to its effectiveness and safety. METHOD: Eighty (80) subjects with PDDs (10 females, 70 males) (mean +/- SD age = 7.7 +/- 3.5 years, range 3-18 years) were treated with guanfacine within an academic specialty clinic. Charts were reviewed to determine the response of specific target symptoms, including hyperactivity, inattention, and impulsivity. The relationship between treatment response and age, diagnosis, level of cognitive impairment, and symptom severity was determined. Adverse effects were also evaluated. RESULTS: Guanfacine (mean daily dose = 2.6 +/- 1.7 mg, range 0.25-9 mg; mean duration of treatment = 334 +/- 374 days, range 7-1776 days) treatment was effective in 19 of 80 (23.8%) subjects. Subjects with PDD not otherwise specified (11 of 28 responders; 39.3%) and Asperger's disorder (2 of 6 responders; 33.3%) showed a greater rate of global response than those with autistic disorder (6 of 46 responders; 13.0 %). There was a trend for subjects without comorbid mental retardation (9 of 24 subjects; 37.5%) to respond at a greater rate than those with mental retardation (10 of 56 subjects; 17.9%). Symptom improvement was seen in hyperactivity, inattention, insomnia, and tics. Guanfacine was well tolerated, and did not lead to significant changes in blood pressure or heart rate. CONCLUSIONS: Guanfacine may have a role in the treatment of hyperactivity and inattention occurring in some persons with PDDs. Further studies are needed to determine its efficacy in this population.

Integrity signals

Registry

Crossref · 10.1089/1044546041649084

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Guanfacine has been reported to be safe and effective in the treatment of hyperactivity and impulsiveness in children with ASD.

    “Guanfacine has been reported to be safe and effective in the treatment of hyperactivity and impulsiveness in children with ASD [52, 53].”

    From An Update on Psychopharmacological Treatment of Autism Spectrum Disorder (2022) · cites this paper as [53]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Posey, D. J., Puntney, J. I., Sasher, T. M., Kem, D. L., & McDougle, C. J.
Affiliations
  • Indiana University Hospital (US)
  • Indiana University School of Medicine (US)
ORCID
McDougle, Christopher J.
Venue
Journal of Child and Adolescent Psychopharmacology
Publisher
SAGE Publications
Published
2004-06
Volume
14
Issue
2
Pages
233-241
ISSN
  • 1044-5463 (ISSN-L)
  • 1557-8992
DOI
10.1089/1044546041649084
OpenAlex
W2038535375
Cited by
127
References
31
Citations by year
2025: 6 · 2024: 7 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 6 · 2015: 5 · 2014: 8 · 2013: 4 · 2012: 9
FWCI
4.87
Type
journal article
Language
en
Open access
closed
Licence
www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
Locations
  • Journal of Child and Adolescent Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (n01mh070001-008)
  • National Institute of Mental Health (N01 MH-70001)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
guanfacine, pervasive developmental disorders, hyperactivity, inattention, impulsivity, Asperger syndrome, autism spectrum disorder, intellectual disability, treatment response, adverse effects, tics, insomnia, children and adolescents
MeSH terms
Adolescent, Adrenergic alpha-Agonists, Aging, Attention Deficit Disorder with Hyperactivity, Child, Child Development Disorders, Pervasive, Child, Preschool, Cognition Disorders, Electrocardiography, Female, Hemodynamics, Humans, Impulsive Behavior, Male, Intellectual Disability, Psychiatric Status Rating Scales, Retrospective Studies, Guanfacine, Asperger Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review